Renal osteodystrophy from secondary hyperparathyroidism is a major cause of morbidity in end-stage renal failure, and in the past· frequently called for recourse to surgical extirpation of the parathyroid glands. The unfavorable course of secondary hyperparathyroidism, however, has been altered by the use of phosphate binders, and the availability and widening use of vitamin D preparations have significantly improved our ability to control the disease medicf111y. The value of these preparations is not restricted to their effect on plasma calcium, but extends to bone changes and PTH secretary dynamics. 1,25(0H)2 vitamin 03 improves hyperparathyroid bone disease, as reflected by a reduction in osteoblast and osteoclast numbers (1 ). Intravenous 1,25 dihydroxycholecalciferol may also have a direct effect on PTH secretion independent of serum calcium (2) .
Modern nephrologic practice has, in a sense, iatrogenically altered the natural history of secondary hyperparathyroidism, and consequently reduced the need for surgical intervention. In a 1971 review of a seven-year dialysis and transplant program, Wilson et al. (3) found that 28 of 800 ESRD patients required subtotal parathyroidectomy, an incidence of 35/1000 or 3.5%. This was in contrast to an overall incidence of first parathyroidectomy in 1983 of 12/1000 patients at risk (4) . These data need to be interpreted in the context of a changing hemodialysis population (older Patients, more patients with diabetic nephropathy, and longer survival). The incidence of parathyroidectomy rises from 5/1000 in the first two to three years to 40/1000 after ten years on dialysis (4). Most parathyroidectomies are now done at an average of ten years after onset of renal failure and 51 months after the first hemodialysis. Subtotal parathyroidectomy is now performed on a smaller percentage of patients at a later stage in their disease largely because of vitamin D therapy.
The ability to control PTH levels by "medical" parathyroidectomy has narrowed the range of indications for the surgical procedure. The main indication now is a hyperparathyroid state with significant target organ damage that is resistant to medical therapy. This would include a progressive increase in iPTH (> 1 OOO µeq/ml), radiographic evidence of subperiosteal resorption or pathological fractures, severe symptomatic hypercalcemia, and calciphylaxis with ischemic lesions of soft tissue or skin, and vascular calcifications. Pruritis, bone pain alone, and aseptic necrosis do not benefit consistently after parathyroidectomy and should not be considered as indications for surgery (5) . Immediately after parathyroidectomy, mean iPTH levels fall dramatically. Alkaline phosphatase and phosphate concentrations decline, subperiosteal resorption decreases, musculoskeletal complaints subside, and symptomatic ectopic calcification improves. Long-term benefits include recalcification of cystic bone disease, usually within six weeks, rapid disappearance of metastatic calcification, and relief of bone and joint pain (3) . Vascular calcifications are reversed slowly if at all, though an improvement in angina after six months has been reported (6) .
The etiology of postoperative hypocalcemia is multifactorial including hypoparathyroidism, skeletal remineralization, and hypomagnesemia. The severity and duration of hypocalcemia depend on the degree of bone demineralization (7) . Felsenfeld et al. (6) found that the maximum decrease in serum calcium was related to the number of osteoclasts/mm 2 on preoperative bone biopsy, and that prolonged hypocalcemia can be predicted if preoperative skeletal erosions exist. Also predictive is the level of alkaline phosphatase. Dawborn et al. (8) described this relationship in that the higher the preoperative alkaline phosphatase, the greater the intravenous calcium requirement postoperatively.
The incidence of reported postoperative hypocalce-Parathyroidectomy mia is variable. Approximately 50% of patients develop hypocalcemia (<8 mg/di) within the first 24 to 48 hours despite treatment with vitamin D for two to five days before surgery. They may need intravenous calcium infusion for from 1 to 15 days, but for more than one week in over half of the patients (8, 9) . The need for intravenous supplementation may be lessened by using both oral calcium salts and vitamin D preparations before and after surgery (5) . Oral calcium supplementation (1 g of elemental Ca) and calcitriol 1 to 3 rncg daily maintains serum calcium between 9.5 and 11 mg/di with overall satisfactory results. Intensive care unit monitoring is prudent in the immediate postoperative period until the degree of hypocalcemia is established. Upon returning from the operating room, intravenous calcium gluconate 4-8 mg/kg/h should be administered postoperatively as a continuous infusion with additional bolus doses for symptomatic hypocalcemia. Intravenous calcitriol may be given from the outset. Supplemental magnesium should be given when serum magnesium levels drop below 1.5 mg/100 ml.
Postoperative oral calcium supplements should be instituted as soon as the patient can tolerate them. Calcium glucoheptonate, citrate or carbonate may be used. Calcitriol is the most useful postoperative vitamin D preparation because of its rapid onset of action. Hypocalcemia may persist for up to two weeks postoperatively with the maximum decrement usually seen within seven days. Once calcium levels are stable and the patient's calcium requirement can be estimated, the patient may be transferred to a general medical floor. Daily calcium levels should be obtained and oral calcium and calcitriol dosages should be adjusted accordingly. Blood calcium levels rise as "hungry" bones are repleted. A clue that rapid skeletal remineralization is nearly complete may be a fall in alkaline phosphatase.
Rarely, tetanic seizures occur two to three weeks post-operatively at a time when calcium levels have stabilized. The etiology is unclear and precipitation by hemodialysis is unexplained.
Aluminium-associated uremic bone disease, a feared long-term complication of parathyroidectomy, is related to enhanced deposition of aluminium. In some patients, unsuspected aluminium-related bone disease may have been the initial cause of the hypercalcemia that led to the parathyroidectomy. In general, alumi-134 nium-associated bone disease has different clinical characteristics from hyperparathyroidism-related bone disease. It is resistant to vitamin D therapy and causes pathological fractures more readily, may be associated with hypercalcemia, and occasionally with increased alkaline phosphatase. Usually serum iPTH is below 500µeq/ml -above the normal limit (50µeq/ ml) but below the range of clearly established hyperparathyroidism shown to benefit from parathyroidectomies (>1000µeq/ml (5)). Parathyroidectomy is contraindicated in these patients because it fails to control the hypercalcemia and may cause worsening of the bone disease (10) .
Another complication is hypoparathyroidism (3.1% (8) ). It may be circumvented by freezing parathyroid tissue and implanting it later if hypocalcemia persists. Hyperparathyroidism may occur because of graftdependent hyperparathyroidism or supernumary glands in the neck or mediastinum. Anatomical studies have shown that 5-6% of patients have five glands and fewer than 1 % have six glands. These are not found because they are small embryologic residues of parathyroid tissue in or near the thymus. It is also believed that autotransplantation may occur due to seeding by islands of cells clipped intraoperatively. The incidence of repeat explorations ranges from 5 to17% (11) .
